Study offers guidance for targeting residual ovarian tumors

Publication Title
MIT News
Publication/Creation Date
May 23 2017
Anne Trafton (creator)
Laura Tanenbaum (contributor)
Aikaterini Mantzavinou (contributor)
Michael Cima (contributor)
Kriti Subramanyam (contributor)
Massachusetts Institute Of Technology (MIT) (contributor)
Koch Institute For Integrative Cancer Research (contributor)
Persuasive Intent
MIT researchers who are working on an implantable device that could make intraperitoneal chemotherapy more bearable have published a new study that offers insight into how to improve chemotherapy strategies for ovarian cancer, and how to determine which patients would be most likely to benefit from this device.
The findings suggest that the outcome of initial surgery plays a key role in the effectiveness of subsequent intraperitoneal chemotherapy. Cisplatin, one of the most commonly used drugs, effectively treats very tiny tumor cell clusters when it is delivered continuously or as a single large dose. But the researchers found that for larger tumor cell clusters, continuous delivery of cisplatin, at higher doses than are tolerable with the current periodic chemotherapy method, was more effective. The device they are developing would make delivery of such higher, continuous doses possible.
HCI Platform
Relation to Body
Related Body Part
Technology Keywords
Drug-Loaded Polymer

Date archived
June 27 2017
Last edited
July 5 2021
How to cite this entry
Anne Trafton. (May 23 2017). "Study offers guidance for targeting residual ovarian tumors". MIT News. MIT News. Fabric of Digital Life.